已发表论文

降糖药物对 PCOS 大鼠下丘脑弓状核 Kisspeptin 表达的影响

 

Authors Zheng P, Lu Y, Tang Y, Xu F, Wang L, Qian R, Hui C, Xu Q, He J, Deng D

Received 17 June 2023

Accepted for publication 23 August 2023

Published 7 September 2023 Volume 2023:16 Pages 2717—2732

DOI https://doi.org/10.2147/DMSO.S421911

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Juei-Tang Cheng

Background: To investigate the change in hypothalamic kisspeptin-1 (Kiss1) expression during the development of polycystic ovary syndrome (PCOS) and hypoglycemic drug intervention.
Methods: Letrozole lavage was used to construct a polycystic ovary rat model. After successful modeling, we treated PCOS rats with metformin, pioglitazone, and acarbose, and we then observed changes in weight, estrus, glucose tolerance, insulin resistance, sex hormones, and hypothalamic kiss1 expression.
Results: PCOS rats exhibited increased body weight, abnormal estrous cycle, impaired glucose tolerance, insulin resistance, increased testosterone level, increased luteinizing hormone level, and increased Kiss1 expression in the hypothalamus. However, intervention with metformin, pioglitazone, and acarbose improved the reproductive and metabolic disorders as well as reduced hypothalamic Kiss1 expression.
Conclusion: The expression of hypothalamic Kiss1 may play an important role in the pathogenesis of PCOS. Metformin, pioglitazone, and acarbose may reduce the expression of hypothalamic Kiss1 by improving insulin resistance, thereby improving reproductive and metabolic disorders in PCOS rats.
Keywords: polycystic ovary syndrome, PCOS, kisspeptin, metformin, pioglitazone, acarbose